Canonical: https://heartbank.net/positions/patent-vs-defensive-publication · Licence: CC0 1.0
Why HeartBank Publishes Every Mechanism to the Commons and Will Never Seek a Patent
HeartBank invents mechanisms: payment primitives, governance patterns, institutional architectures. The conventional move for an institution that invents is to patent — to secure a time-limited legal monopoly and the right to exclude others from practising the invention. HeartBank declines that move, permanently and in every jurisdiction.
Instead, HeartBank defensively publishes every mechanism it invents: it places a full, timestamped, public-domain description into the commons under the Creative Commons CC0 dedication, so that the mechanism can never be patented by anyone — including HeartBank — and can be freely implemented, modified, translated, and republished by anyone. This is a permanent institutional constraint, not a tactic awaiting better circumstances.
A defensive publication delivers the one protection HeartBank actually needs — freedom to operate, secured by prior art — while discarding the one thing HeartBank does not want: the power to exclude. The position is reasoned here for foundation, legal, and policy audiences, and it is recorded as a binding commitment so that no future steward of the institution, human or autonomous, inherits the option to reverse it. Trademarks are the deliberate exception, and §5 explains why a trademark is not a patent.
HeartBank will not seek, hold, or enforce a patent on any mechanism, primitive, architecture, or specification it invents, in any jurisdiction, at any time. Every such invention is instead defensively published: a complete description is placed in the public domain under the Creative Commons CC0 1.0 dedication, across a multi-venue wall of independently-timestamped mirrors, as soon as it is mature enough to publish. The research corpus at thonly.org is the canonical record of this practice.
Two protections must be distinguished. A patent gives its holder (a) freedom to operate — the assurance that no one else can stop them practising their own invention — and (b) the right to exclude others from practising it. A defensive publication gives (a) and only (a).
Once a mechanism is publicly described with a credible, independent timestamp, it is prior art. No one can subsequently patent it, and therefore no one can use a later patent to block HeartBank from practising its own work. HeartBank obtains the freedom-to-operate protection in full, and forgoes only the exclusion right. The institution's position is that (a) is a genuine need and (b) is a liability — which §3 sets out.
The mission. HeartBank exists to spread gratitude infrastructure as widely as possible. A patent's function is to restrict who may build; the mission's function is to maximize who builds. The instrument and the goal point in opposite directions. Every mechanism HeartBank invents serves the mission more, not less, the more freely it spreads — including spread by parties who have never heard of HeartBank.
The asymmetry of duration. A patent is a monopoly of roughly twenty years that then lapses. A defensive publication is permanent prior art. For an institution built to operate across centuries, the permanent instrument is the correct one; a temporary monopoly is a small, expiring benefit purchased at the cost of two decades of restricted adoption during the very period when adoption matters most.
The posture. Patent enforcement is adversarial, expensive, and slow — litigation, licensing negotiations, and a legal apparatus pointed at other builders. An institution whose autonomous successor will one day be entrusted with planetary-scale infrastructure cannot credibly be an institution that litigates to exclude. Trust is the asset; an exclusion portfolio spends it.
HeartBank states this as a constraint, not a current preference, for the same reason it binds its non-bank and its no-engagement-advertising positions: a door left open is a door through which future pressure enters. An institution that merely holds the option to patent will, under financial or competitive stress, eventually face the argument that it should. By publishing every mechanism into the commons as it is invented, HeartBank removes the option itself — the mechanism becomes unpatentable by anyone, HeartBank included, the instant it is published. There is no portfolio to be tempted by, and no asset a future steward can be pressured to monetize.
This matters most for what HeartBank is building toward. The institution is designed to be inherited — by Miss Aquarius, its autonomous-AI substrate, and by the body that holds her override. A successor that inherited a patent portfolio would inherit both the power to exclude and the standing pressure to enforce it. A successor that inherits a defensively-published commons inherits neither. The choice made now is, deliberately, a failure mode removed from the future.
HeartBank does reserve trademark rights — on the name HeartBank, on Miss Aquarius, on the B-heart logo, and on the B-prefix marks. This is not an inconsistency, because a trademark and a patent do opposite work.
A patent restricts who may build a mechanism. A trademark restricts who may claim to be HeartBank. The first narrows the commons; the second protects the public's ability to know what is genuinely the institution and what is not — which is itself a service to the commons, and which becomes more important, not less, as the mechanisms spread freely under CC0 and many parties build with them. Anyone may implement every HeartBank mechanism; no one may misrepresent their implementation as HeartBank itself. Trademark protects identity; it does not restrict invention.
A patent portfolio is a counter-suit deterrent, and defensive publication is not. Prior art stops anyone patenting HeartBank's inventions. It does nothing against a patent someone else already holds. When a large firm asserts a patent against a small one, the small firm's most effective defence is often its own portfolio — the threat of a counter-claim that makes litigation mutually expensive. That is the logic of defensive patenting and of pools such as the Open Invention Network, and many mission-driven organisations adopt it for exactly that reason. HeartBank forgoes it entirely, and if a holder of an unrelated patent asserts it, the institution will have prior art on what it published and no leverage beyond that.
Publication also teaches. A defensive publication is written to be implementable, which makes it as useful to a well-resourced competitor as to anyone else. The institution's posture already concedes the boundary — publication protects against being blocked, not against being beaten — which is why the corpus withholds complete specifications for products that are unbuilt and unscheduled, publishing the claim without the blueprint. And there is a fundraising cost: investors read a portfolio as evidence of defensibility, and an institution with none must be defensible some other way.
Volvo's three-point seatbelt is the canonical case — patented in 1959 and opened to the industry rather than enforced, on the reasoning that universal adoption was worth more than exclusivity.
Tesla's 2014 patent pledge is the modern case, and the difference is the important part. Tesla did not abandon its patents; it announced it would not sue good-faith users. A pledge is revocable, conditional, and interpreted by the party who made it. The patents still exist, and a successor management could re-read the conditions. A CC0 dedication is a different object: the mechanism enters the public domain and no one can patent it afterwards — including HeartBank, and including whoever owns HeartBank in fifty years. That irreversibility is the point, and it is why the institution publishes rather than pledges. The difference between a promise not to enforce and an inability to enforce is the difference between a rule and a property.
IBM's Technical Disclosure Bulletin is the operational precedent — decades of deliberate defensive publication by an organisation that also held one of the world's largest patent portfolios, which is a reminder that the practice is established professional technique rather than idealism, and that IBM used it alongside patents. HeartBank's position is the rarer one: publication instead of, not in addition to.
Nothing on the ordinary list. The discovery that a mechanism is commercially valuable would not — that is when the temptation arrives and what this is written against. A competitor's success with a published mechanism would not; that outcome is the mission working. Investor preference would not. Litigation pressure would not, because the deterrent argument was answered above and answered before the pressure existed, which is the only time such an answer is worth anything.
If a third party patents something adjacent and uses it to block work HeartBank needs to do, the response is to publish faster and more completely into that space, widening the prior art — not to begin patenting. The remedy for a blocked road is more commons, not a toll booth of one's own. The argument for why a class of permanent self-bindings is worth having at all, and the honest admission that these three are published intentions not yet structurally enforced, is set out in HeartBank Is Not a Bank §5.5 rather than repeated here.
HeartBank commends defensive publication to every mission-driven institution that invents — particularly those, like itself, whose purpose is served by adoption rather than by exclusion. The reasoning is not unique to gratitude infrastructure. Any institution whose goal is for a thing to exist widely, rather than for itself to be the sole provider, will find that the patent's exclusion right is a cost and the defensive publication's prior-art shield is the whole of the benefit it actually wanted. HeartBank's corpus is offered, in its entirety and permanently, on those terms.